Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liam Welsh

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastomaCrescens Tiu, Wing Yau, Diogo Silva, et al.
Neuro-Oncology|January 29, 2024
Glioblastoma and radiotherapy: A multicenter AI study for Survival Predictions from MRI (GRASP study)Alysha Chelliah, David A Wood, Liane S Canas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Research Square|September 28, 2021
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Nature Cancer|December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastomaCrescens Tiu, Wing Yau, Diogo Silva, et al.
Neuro-Oncology|January 29, 2024
Glioblastoma and radiotherapy: A multicenter AI study for Survival Predictions from MRI (GRASP study)Alysha Chelliah, David A Wood, Liane S Canas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populationsRita Pereira, Alan Mackay, Yura Grabovska, et al.
Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Research Square|September 28, 2021
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Nature Cancer|December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 6